Our Technologies
And Pipeline

Our Technologies

Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases. Our diversified portfolio is designed to treat vision-threatening diseases of the retina, optic nerve, and cornea, by either maintaining effective drug levels in ocular tissues for long periods of time, using innovative technologies such as injectable sustained-release formulations, or by curing diseases with gene therapies.

Our Gene Therapy APPROACH

Graybug’s gene therapy platform is based on recombinant adeno-associated virus (rAAV) technology designed to deliver a functional copy of the gene that encodes alpha-L-iduronidase (IDUA), an enzyme that breaks down intracellular and extracellular glycosaminoglycans (GAGs), directly to the cornea of Mucopolysaccharidosis Type 1 patients (MPS1) with a single injection.

Ocular Sustained
Release Technologies

Our proprietary technologies are designed to allow sustained delivery of pharmacologic agents to the eye in a well-controlled manner to achieve extended duration of effectiveness with the goal of

  • Improving patient compliance
  • Reducing healthcare burden
  • Improving clinical outcomes
Designed to Promote Controlled, Sustained Drug Delivery
Microparticle technology
Graybug’s polymer delivery system is designed to form a depot near the bottom of the eye, outside of the visual axis, as microparticles that aggregate after intravitreal (IVT) injection. Our biodegradable drug product gradually releases the active ingredient at a rate designed to provide the desired treatment duration. It then biodegrades into lactic acid, glycolic acid and polyethylene glycol, all of which are then naturally cleared from the body.
Designed to Promote Controlled, Sustained Drug Delivery
Implant technology
Graybug’s implant technology is designed to inject a rod-shaped implant into the vitreous of the eye, outside of the visual axis, with the help of a proprietary applicator. Our biodegradable implant gradually releases the payload at a rate designed to provide the desired treatment durability. It then biodegrades into lactic acid, glycolic acid and polyethylene glycol, all of which are then naturally cleared from the body. 
Our diversified portfolio is designed to treat vision-threatening diseases of the retina, cornea as well as the optic nerve.

Our Pipeline

Applying Our Proprietary Technologies to Our Pipeline

Our diversified pipeline includes compounds in research, preclinical and phase 2 clinical development.
Click on each compound to learn more.